- |||||||||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Enrollment change, Trial primary completion date: Pregnancy Exposure Registry for Tysabri® (clinicaltrials.gov) - Aug 11, 2014 P=N/A, N=376, Completed, Recruiting --> Completed | N=300 --> 376 | Trial primary completion date: Jun 2016 --> Jul 2012
- |||||||||| Orencia (abatacept) / BMS
Enrollment change, Trial initiation date, Trial primary completion date: Methotrexate-Inadequate Response Study (clinicaltrials.gov) - Aug 8, 2014 P3, N=1482, Completed, Recruiting --> Completed | N=300 --> 376 | Trial primary completion date: Jun 2016 --> Jul 2012 N=62 --> 1482 | Initiation date: Nov 2009 --> Jan 2008 | Trial primary completion date: Feb 2010 --> Nov 2009
- |||||||||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 (clinicaltrials.gov) - Aug 8, 2014 P1, N=0, Recruiting, Initiation date: Mar 2014 --> Sep 2014 | Trial primary completion date: Mar 2016 --> Sep 2016 Not yet recruiting --> Recruiting
- |||||||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment closed: Long-Term Efficacy and Safety of CT-P10 in Patients With RA (clinicaltrials.gov) - Aug 6, 2014 P1, N=102, Active, not recruiting, Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- |||||||||| Orencia (abatacept) / BMS
P4 data, Trial primary completion date: Korean Post-marketing Surveillance for Orencia® (clinicaltrials.gov) - Aug 5, 2014 P=N/A, N=600, Recruiting, Recruiting --> Active, not recruiting | N=172 --> 215 Trial primary completion date: Mar 2016 --> Jul 2016
- |||||||||| Phase classification, Enrollment change, Trial termination, Trial primary completion date: Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=144, Terminated, Trial primary completion date: Mar 2016 --> Jul 2016 Phase classification: P4 --> P=N/A | N=250 --> 144 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2021 --> Jun 2014; Study was stopped due to low follow-up compliance at study sites.
- |||||||||| Enrollment closed, Trial primary completion date: LARMES: Tear Analysis in the Diagnosis of Multiple Sclerosis (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=100, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2016
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed: Islet After Kidney Transplant for Type 1 Diabetes (clinicaltrials.gov) - Aug 5, 2014 P1/2, N=10, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Trial completion, Enrollment change, Trial primary completion date: Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination (clinicaltrials.gov) - Aug 4, 2014 P=N/A, N=1516, Completed, Recruiting --> Completed | N=380 --> 28 | Trial primary completion date: Oct 2015 --> Apr 2014 Recruiting --> Completed | N=140000 --> 1516 | Trial primary completion date: Jun 2014 --> Sep 2013
- |||||||||| Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
Enrollment closed: IIT6: Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design (clinicaltrials.gov) - Aug 1, 2014 P=N/A, N=30, Active, not recruiting, Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jul 2014; The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951. Recruiting --> Active, not recruiting
|